Company Description
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment.
The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 5, 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Jeffrey Hackman |
Contact Details
Address: 68 TW Alexander Drive, PO Box 13628 Research Triangle Park, North Carolina 27709 United States | |
| Phone | 919 636 4530 |
| Website | fennecpharma.com |
Stock Details
| Ticker Symbol | FENC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001211583 |
| CUSIP Number | 31447P100 |
| ISIN Number | CA31447P1009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey S. Hackman | Chief Executive Officer and Director |
| Robert C. Andrade | Chief Financial Officer |
| Dr. Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer |
| Terry Evans | Chief Commercial Officer |
| Christiana Cioffi M.B.A. | Chief Strategy Officer |
| Mark Gowland | Controller |
| Lei Fang | President of Pharstat Inc |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 144 | Filing |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Feb 2, 2026 | 144 | Filing |
| Jan 14, 2026 | SCHEDULE 13G/A | Filing |
| Jan 2, 2026 | 144 | Filing |
| Dec 9, 2025 | 8-K | Current Report |